Empowered Patient Podcast

Roger Rivera, psychiatric mental health nurse practitioner at Mente Suave Psychiatry, discusses the different types of bipolar disorder, the potential causes of the disease, available treatment options, and the importance of early detection and management. Roger emphasizes the need for a comprehensive approach to care and highlights the impact of bipolar disorder on patients' lives and society as a whole. While there are currently no biological markers for bipolar disorder, ongoing research and initiatives, including the use of AI, show promise in improving diagnosis and treatment.

Roger explains, "So rather than bipolar disorder, it should probably be called bipolar disorders just because of the different manifestations that it has. One of those manifestations could be manic episodes. Manic episodes could be described as just expansive mood, inflated self-esteem, decreased need for sleep, more targeted flight of ideas, and all these other things, which have a very strong correlation with functional impairment. And that's just one of the variations of bipolar disorder."

"We also have bipolar II, which has more hypomanic type features. So, if we look at the diagnostic manual that we use in psychiatry, we'll see that for bipolar I, it highlights we need at least one manic episode, but we didn't need a depressive episode. Yet, when we look at bipolar II, we usually need at least one depressive episode associated with that."

#BipolarDisorder #MentalHealthAwareness #TreattheWholePatient #BipolarTreatment #PatientEngagement

mentesuavepsychiatry.com

Listen to the podcast here

Roger Rivera, psychiatric mental health nurse practitioner at Mente Suave Psychiatry, discusses the different types of bipolar disorder, the potential causes of the disease, available treatment options, and the importance of early detection and management. Roger emphasizes the need for a comprehensive approach to care and highlights the impact of bipolar disorder on patients' lives and society as a whole. While there are currently no biological markers for bipolar disorder, ongoing research and initiatives, including the use of AI, show promise in improving diagnosis and treatment.

Roger explains, "So rather than bipolar disorder, it should probably be called bipolar disorders just because of the different manifestations that it has. One of those manifestations could be manic episodes. Manic episodes could be described as just expansive mood, inflated self-esteem, decreased need for sleep, more targeted flight of ideas, and all these other things, which have a very strong correlation with functional impairment. And that's just one of the variations of bipolar disorder."

"We also have bipolar II, which has more hypomanic type features. So, if we look at the diagnostic manual that we use in psychiatry, we'll see that for bipolar I, it highlights we need at least one manic episode, but we didn't need a depressive episode. Yet, when we look at bipolar II, we usually need at least one depressive episode associated with that."

#BipolarDisorder #MentalHealthAwareness #TreattheWholePatient #BipolarTreatment #PatientEngagement

mentesuavepsychiatry.com

Download the transcript here

Punit Dhillon, Chairman and CEO of Skye Bioscience, focuses on anti-obesity and developing a drug that targets the cannabinoid receptor 1, which plays a role in signaling the body to store fat. The next generation of CB1 inhibition moves from a centrally mediated pathway to targeting CB1 receptors outside the brain. Deploying the endocannabinoid system, their lead drug candidate targets the major organs where CB1 receptors reside in fat tissue to increase mitochondrial activity and burn more fat.

Punit explains, "Skye is focused on exploring research modulating different therapeutic targets via the endocannabinoid system. Our research has narrowed in on the CB1 receptor, where we're modulating it by focusing on this pathway of inhibition. There's a big body of evidence, actually existing validation of this cannabinoid receptor 1 being a really important target to reduce caloric food intake and increase energy expenditure. It's been a really important target for weight loss because of its particular relevance in that therapeutic area. So we're advancing in a very interesting clinical pipeline and immediately a Phase 2 study that will look at that particular target. We hope that we will be able to show its relevance in the anti-obesity medication landscape."

"I feel like the current landscape of drugs that have been getting the most attention has been focused on caloric restriction. Weight loss is driven by that particular pathway of restricting the amount you eat. We are trying to shift that paradigm to the opportunity to address the underlying issues relating to weight loss so you can essentially have this aspect of targeting fat and being able to address fat metabolism. That comes back to this link to the exercise comment you made because it's driving the underlying mitochondrial activity, which is helping to improve the thermogenesis and the conversion of that fat into thermogenic energy."

#SkyeBioscience #Obesity #EndocannabinoidSystem #WeightLossDrug #CB1Receptor #GLP1

skyebioscience.com

Listen to the podcast here

Punit Dhillon, Chairman and CEO of Skye Bioscience, focuses on anti-obesity and developing a drug that targets the cannabinoid receptor 1, which plays a role in signaling the body to store fat. The next generation of CB1 inhibition moves from a centrally mediated pathway to targeting CB1 receptors outside the brain. Deploying the endocannabinoid system, their lead drug candidate targets the major organs where CB1 receptors reside in fat tissue to increase mitochondrial activity and burn more fat.

Punit explains, "Skye is focused on exploring research modulating different therapeutic targets via the endocannabinoid system. Our research has narrowed in on the CB1 receptor, where we're modulating it by focusing on this pathway of inhibition. There's a big body of evidence, actually existing validation of this cannabinoid receptor 1 being a really important target to reduce caloric food intake and increase energy expenditure. It's been a really important target for weight loss because of its particular relevance in that therapeutic area. So we're advancing in a very interesting clinical pipeline and immediately a Phase 2 study that will look at that particular target. We hope that we will be able to show its relevance in the anti-obesity medication landscape."

"I feel like the current landscape of drugs that have been getting the most attention has been focused on caloric restriction. Weight loss is driven by that particular pathway of restricting the amount you eat. We are trying to shift that paradigm to the opportunity to address the underlying issues relating to weight loss so you can essentially have this aspect of targeting fat and being able to address fat metabolism. That comes back to this link to the exercise comment you made because it's driving the underlying mitochondrial activity, which is helping to improve the thermogenesis and the conversion of that fat into thermogenic energy."

#SkyeBioscience #Obesity #EndocannabinoidSystem #WeightLossDrug #CB1Receptor #GLP1

skyebioscience.com

Download the transcript here

Joe Ferra, CEO of Elevation Oncology, highlights the unmet needs in gastric cancer and the potential of targeting Claudins, proteins involved in cell adhesion. The current competitive landscape of antibody drug conjugates (ADCs) confirms the promise of a targeted therapy that delivers a cytotoxic drug directly to cancer cells. Targeting Claudin 18.2 with an ADC approach offers an opportunity to treat a broader range of tumors expressing a lower level of Claudin 18.2 than those currently treated by CAR-T therapy. This approach is being investigated as a single-agent drug with promise for use in combination for gastric cancer, pancreatic cancer and esophageal cancer.

Joe explains, "As you likely know, in the continuum of cancer drugs, you have chemotherapy on one end that indiscriminately kills everything it touches. On the other end, you have uber-targeted therapies looking at specific drivers of what's driving that specific tumor. In our case at Elevation Oncology, we're focused on what we like to call selected targeted oncology drugs so that we are using the unique characteristics of the tumor to target and meet in a targeted way attempt to kill the tumor for a better outcome for the patient."

"Gastric cancer in and of itself was an area where Claudin 18.2 is known to be highly expressed, but for gastric cancer, to your point, there's a huge unmet need. For most patients, once they're in second line or third line, the opportunity for drugs that are available to them today is, unfortunately for all of us, very dismal. We think there's a significant opportunity to utilize a Claudin 18.2 antibiotic drug conjugate for overall better outcomes for patients living with gastric cancer."

"We quickly saw an ADC approach as an opportunity to treat a broader range of Claudin 18.2 expression. Now, as I'm sure you're aware, in any target in any tumor, there's always a range of expression for Claudin 18.2. In gastric cancer, it's known that as much as 80% of gastric cancer expressed Claudin 18.2 at some level. With that expression, we think an ADC approach will be able to treat a broader range of expression."

#ElevationOncology #ADC #AntibodyDrugConjugate #SolidTumors #Claudin182 #Claudins #Cancer

ElevationOncology.com

Listen to the podcast here

Joe Ferra, CEO of Elevation Oncology, highlights the unmet needs in gastric cancer and the potential of targeting Claudins, proteins involved in cell adhesion. The current competitive landscape of antibody drug conjugates (ADCs) confirms the promise of a targeted therapy that delivers a cytotoxic drug directly to cancer cells. Targeting Claudin 18.2 with an ADC approach offers an opportunity to treat a broader range of tumors expressing a lower level of Claudin 18.2 than those currently treated by CAR-T therapy. This approach is being investigated as a single-agent drug with promise for use in combination for gastric cancer, pancreatic cancer and esophageal cancer.

Joe explains, "As you likely know, in the continuum of cancer drugs, you have chemotherapy on one end that indiscriminately kills everything it touches. On the other end, you have uber-targeted therapies looking at specific drivers of what's driving that specific tumor. In our case at Elevation Oncology, we're focused on what we like to call selected targeted oncology drugs so that we are using the unique characteristics of the tumor to target and meet in a targeted way attempt to kill the tumor for a better outcome for the patient."

"Gastric cancer in and of itself was an area where Claudin 18.2 is known to be highly expressed, but for gastric cancer, to your point, there's a huge unmet need. For most patients, once they're in second line or third line, the opportunity for drugs that are available to them today is, unfortunately for all of us, very dismal. We think there's a significant opportunity to utilize a Claudin 18.2 antibiotic drug conjugate for overall better outcomes for patients living with gastric cancer."

"We quickly saw an ADC approach as an opportunity to treat a broader range of Claudin 18.2 expression. Now, as I'm sure you're aware, in any target in any tumor, there's always a range of expression for Claudin 18.2. In gastric cancer, it's known that as much as 80% of gastric cancer expressed Claudin 18.2 at some level. With that expression, we think an ADC approach will be able to treat a broader range of expression."

#ElevationOncology #ADC #AntibodyDrugConjugate #SolidTumors #Claudin182 #Claudins #Cancer

ElevationOncology.com

Download the transcript here

Dr. Steve Goldberg, physician and Senior Clinical Advisor at DecisionRx, and Dr. Jamie Wilkey, pharmacist and expert on medication therapy optimization, explain that medications are the fourth leading cause of death in the country. They emphasize the need to consider genetic information and pharmacogenomics to design personalized medication plans to improve health outcomes. The DecisionRx solution is integrated into the pharmacist's workflow to improve medication safety, reduce avoidable costs, and enhance communication with providers, pharmacists, and patients.

Steven explains, "Our goal is to help people get more benefits from the medications that they use. A couple of starting facts. The US spends about $500 billion-plus a year on medication, and sadly, there are hundreds of thousands of ER visits, hospitalizations, and deaths that occur to people attributable to medications. There are a number of reasons for it, but relative to what we do, it is often triggered by people having genetics that make them not do well with particular medication. It's often the regimen that they're on has too many drugs, and that creates a problem. Finally, and potentially most importantly, they're not taking the time or not given the time to have their medication regimen carefully reviewed by a well-trained pharmacist to help organize things for the best outcomes. And best outcomes, reduce health risks, control chronic disease, and provide treatment."

Jamie elaborates, "We also consider the genetics of people taking their medication, which has been overlooked significantly in the past. Specifically, the way our body metabolizes medication is so different based on ethnicity, background, and gender, and you can't just tell by looking at a person how they'll metabolize medication. We can finally understand what medication is likely to work for a person, which is unlikely to work, and what is probably going to give them a lot of terrible adverse reactions before the patient has to go home and try it."

#DecisionRx #Healthcare #MedicationTherapyOptimization #PrecisionMedicine #Pharmacogenomics #HealthcareInnovation

decisionrx.com

Listen to the podcast here

Dr. Steve Goldberg, physician and Senior Clinical Advisor at DecisionRx, and Dr. Jamie Wilkey, pharmacist and expert on medication therapy optimization, explain that medications are the fourth leading cause of death in the country. They emphasize the need to consider genetic information and pharmacogenomics to design personalized medication plans to improve health outcomes. The DecisionRx solution is integrated into the pharmacist's workflow to improve medication safety, reduce avoidable costs, and enhance communication with providers, pharmacists, and patients.

Steven explains, "Our goal is to help people get more benefits from the medications that they use. A couple of starting facts. The US spends about $500 billion-plus a year on medication, and sadly, there are hundreds of thousands of ER visits, hospitalizations, and deaths that occur to people attributable to medications. There are a number of reasons for it, but relative to what we do, it is often triggered by people having genetics that make them not do well with particular medication. It's often the regimen that they're on has too many drugs, and that creates a problem. Finally, and potentially most importantly, they're not taking the time or not given the time to have their medication regimen carefully reviewed by a well-trained pharmacist to help organize things for the best outcomes. And best outcomes, reduce health risks, control chronic disease, and provide treatment."

Jamie elaborates, "We also consider the genetics of people taking their medication, which has been overlooked significantly in the past. Specifically, the way our body metabolizes medication is so different based on ethnicity, background, and gender, and you can't just tell by looking at a person how they'll metabolize medication. We can finally understand what medication is likely to work for a person, which is unlikely to work, and what is probably going to give them a lot of terrible adverse reactions before the patient has to go home and try it."

#DecisionRx #Healthcare #MedicationTherapyOptimization #PrecisionMedicine #Pharmacogenomics #HealthcareInnovation

decisionrx.com

Download the transcript here

Ryne Natzke is the Chief Revenue Officer for TrustCommerce, a Sphere company that facilitates electronic payments in the healthcare industry, helping ensure security and compliance in transactions between patients and providers. Healthcare payments present unique challenges, as patients have varying preferences and are impacted by economic factors on their ability to make healthcare payments. TrustCommerce aims to make the payment process easier for patients by integrating with electronic health record systems and patient billing systems, reducing friction in healthcare payments and providing patients with more options and transparency in pricing.

Ryne explains, "Some people like paying online, and some people pay in person. There are payment plans. So what we do with our technology and our partnerships with EHRs like Epic and patient billing systems is help make sure that they can facilitate those patient financial experiences across the board and have that happen within systems they're already using. So within MyChart, for example, or just while the patient's checking in at the front desk. We help take that PCI compliance and security piece off the shoulders of our partners and our healthcare systems using our technology."

"Nobody really plans to have a disease like cancer, and all of a sudden, you have a whole bunch of oncology appointments or plans on getting into a car accident and showing up in the emergency room. So it's not really a budgetable expense the same way as I'm going to save up for a Peloton or a new TV or whatever it is. So you're kind of balancing this unknown of what the balance is and being able to line up what that patient might be able to do. Somebody might be able to pay a $2,000 bill when they receive it, and a lot of people can't. So how can we put them on a payment plan and be empathetic of where they are within their situations while also still having all of the compliance and security pieces that come with the transactions?"

#TrustCommerce #TransparencyinPricing #HealthcareCosts #HealthcarePayments

trustcommerce.com

Listen to the podcast here

Ryne Natzke is the Chief Revenue Officer for TrustCommerce, a Sphere company that facilitates electronic payments in the healthcare industry, helping ensure security and compliance in transactions between patients and providers. Healthcare payments present unique challenges, as patients have varying preferences and are impacted by economic factors on their ability to make healthcare payments. TrustCommerce aims to make the payment process easier for patients by integrating with electronic health record systems and patient billing systems, reducing friction in healthcare payments and providing patients with more options and transparency in pricing.

Ryne explains, "Some people like paying online, and some people pay in person. There are payment plans. So what we do with our technology and our partnerships with EHRs like Epic and patient billing systems is help make sure that they can facilitate those patient financial experiences across the board and have that happen within systems they're already using. So within MyChart, for example, or just while the patient's checking in at the front desk. We help take that PCI compliance and security piece off the shoulders of our partners and our healthcare systems using our technology."

"Nobody really plans to have a disease like cancer, and all of a sudden, you have a whole bunch of oncology appointments or plans on getting into a car accident and showing up in the emergency room. So it's not really a budgetable expense the same way as I'm going to save up for a Peloton or a new TV or whatever it is. So you're kind of balancing this unknown of what the balance is and being able to line up what that patient might be able to do. Somebody might be able to pay a $2,000 bill when they receive it, and a lot of people can't. So how can we put them on a payment plan and be empathetic of where they are within their situations while also still having all of the compliance and security pieces that come with the transactions?"

#TrustCommerce #TransparencyinPricing #HealthcareCosts #HealthcarePayments

trustcommerce.com

Download the transcript here